Barinthus Biotherapeutics plc (BRNS)

Market Cap	55.84M
Revenue (ttm)	334,000
Net Income (ttm)	-70.72M
Shares Out	38.95M
EPS (ttm)	-1.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,669
Open	1.415
Previous Close	1.420
Day's Range	1.410 - 1.450
52-Week Range	1.210 - 5.100
Beta	-0.45
Analysts	Strong Buy
Price Target	5.50 (+281.94%)
Earnings Date	Aug 8, 2024

About BRNS

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human p...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2021
• Employees: 130
• Stock Exchange: NASDAQ
• Ticker Symbol: BRNS

Analyst Forecast

According to 2 analysts, the average rating for BRNS stock is "Strong Buy." The 12-month stock price forecast is $5.5, which is an increase of 281.94% from the latest price.

Price Target

$5.5

(281.94% upside)

Analyst Consensus: Strong Buy